ProNAi Therapeutics Inc (DNAI) : Adams Street Partners reduced its stake in ProNAi Therapeutics Inc by 34.17% during the most recent quarter end. The investment management company now holds a total of 738,422 shares of ProNAi Therapeutics Inc which is valued at $1,388,233 after selling 383,293 shares in ProNAi Therapeutics Inc , the firm said in a disclosure report filed with the SEC on Aug 10, 2016.ProNAi Therapeutics Inc makes up approximately 0.22% of Adams Street Partners’s portfolio.
Other Hedge Funds, Including , Blackrock Group Ltd sold out all of its stake in DNAI during the most recent quarter. The investment firm sold 3,158 shares of DNAI which is valued $5,937. Swiss National Bank sold out all of its stake in DNAI during the most recent quarter. The investment firm sold 31,538 shares of DNAI which is valued $62,130. Minerva Advisors added DNAI to its portfolio by purchasing 114,309 company shares during the most recent quarter which is valued at $225,189. ProNAi Therapeutics Inc makes up approx 0.15% of Minerva Advisors’s portfolio.Alps Advisors Inc boosted its stake in DNAI in the latest quarter, The investment management firm added 8,586 additional shares and now holds a total of 42,389 shares of ProNAi Therapeutics Inc which is valued at $86,474.
ProNAi Therapeutics Inc closed down -0.01 points or -0.53% at $1.89 with 3,41,979 shares getting traded on Friday. Post opening the session at $1.9, the shares hit an intraday low of $1.87 and an intraday high of $1.91 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
Many Wall Street Analysts have commented on ProNAi Therapeutics Inc. ProNAi Therapeutics Inc was Downgraded by Jefferies to ” Hold” on Jun 6, 2016. ProNAi Therapeutics Inc was Downgraded by SunTrust to ” Neutral” on Jun 6, 2016.
ProNAi Therapeutics Inc. is a clinical-stage oncology company. The Company develops and commercializes a portfolio of therapeutics based on its deoxyribonucleic acid interference (DNAi) technology platform for patients with cancer and hematological diseases. The Company’s lead DNAi product candidate PNT2258 treat cancers that overexpress BCL2 an oncogene known to be dysregulated in many types of cancer. Its platform consists of two components: Rationally-Designed DNAi Oligonucleotides and Lipid Nanoparticle (LNP) Delivery Technology. The Company has conducted two clinical trials for PNT2258: a Phase I safety trial in patients with relapsed or refractory solid tumors and a Phase II trial in patients with relapsed or refractory non-Hodgkins lymphoma (NHL). It has initiated Wolverine a Phase II trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.